AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06138184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticoagulation Educational Materials
Description: This includes new web-based patient educational materials that have been developed prior to the start of the study
Study NCT06138184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Standard of Care
Description: This will be the current practice for patient education
Study NCT06113614 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Simulation of photobiomodulation
Description: The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 1mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 1mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 2mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 2mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 4mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 4mg/Kg
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo CBD
Description: Participants will ingest soft gel tablets containing placebo for CBD
Study NCT05049733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CBD
Description: Participants will ingest soft gel tablets containing placebo for CBD
Study NCT05611125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Integrated Primary Care (TIPC)
Description: The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
Study NCT05378659 — intervention group
Intervention type: BEHAVIORAL
Intervention: Montreal Cognitive Assessment
Description: Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
Study NCT05378659 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stroop Test
Description: Evaluates Processing Speed and Executive Control
Study NCT06435793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEP measurement - Surface EMG - IOPI
Description: Participants will undergo serial expiratory maneuvers using variously-sized circular mouthpieces and a reference ovoid-shaped mouthpiece.~At each maneuver, the maximal expiratory mouth pressure at total lung capacity will be measured, alongside with the degree of neuromuscular activation of the internal oblique and transverse abdominal muscles using surface electromyography.~The Orbicularis Oris strength will also be measured using the Iowa Oral Performance Instrument.
Study NCT05701345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMNIFIT DTx-MDD
Description: This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
Study NCT05701345 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.
Study NCT05701345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.
Study NCT06525454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized coaching messages for blood glucose and emotions
Description: For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires.
Study NCT04615988 — intervention group
Intervention type: OTHER
Intervention: blood draw and questionnaire completion
Description: questionaires provided to subjects during visits while on study and baseline one tube of blood drawn
Study NCT06315322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Film-coated tablet
Description: Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
Study NCT05378659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 4AT Delirium
Description: Screening tool to test for delirium post surgery
Study NCT05378659 — intervention group
Intervention type: BEHAVIORAL
Intervention: Grooved Pegboard
Description: Evaluation testing for dominant and non dominant sensory-motor speed
Study NCT05378659 — intervention group
Intervention type: BEHAVIORAL
Intervention: NACC Cognitive Battery
Description: A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
Study NCT05378659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ERP Testing
Description: An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
Study NCT04615988 — intervention group
Intervention type: OTHER
Intervention: questionnaire completion, blood collection
Description: questionnaire provided to subject during study visits. One tube blood collected for research purposes at baseline
Study NCT06315322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam oral solution
Description: Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
Study NCT05378659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Plasma and Serum sampling
Description: Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
Study NCT05378659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Spinal Fluid Sample
Description: At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
Study NCT05301348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Flow Cytometry
Description: Detection of circulating blood clots
Study NCT06352216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)
Description: Each subject is examined for the presence of synovitis using the aforementioned diagnostics.
Study NCT06209320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lower dose atropine sulfate eye drops
Description: administer to eyes
Study NCT06209320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose atropine sulfate eye drops
Description: administer to eyes
Study NCT06209320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administer to eyes
Study NCT06685107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Analgesia
Description: Analgesia as determined by the treating physician
Study NCT06685107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Analgesia + Virtual Reality
Description: Analgesia as determined by the treating physician and Virtual Reality experience that will use a geriatric-focused VR platform that has age appropriate VR content and will run for approximately 5-10 minutes
Study NCT06681896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice
Description: MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.~Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour personal trainer (PT) supervised exercise sessions. 45 minute homework exercise session once a week.~Diet: 1-hour educational session with a dietician, followed by two 30-minute follow up sessions.~Phase 2 - Consolidation (10 weeks) Exercise: Once weekly 1 hour PT sessions, two 45 minute homework sessions once a week.~Diet: 30-minute sessions every 5 weeks.~Phase 3 - Maintenance (6 weeks) Exercise: Supervised 1 hour PT sessions once every 3 weeks, 45-minute homework sessions three times a week.~Diet: one final 30 minute session after week 3.
Study NCT04468321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.
Study NCT04468321 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Withings Move
Description: Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.
Study NCT05236062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic and resistance exercise
Study NCT05236062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention control
Description: stretching
Study NCT06095596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
Study NCT06095596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
Study NCT06095596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
Study NCT06622668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological NTLA-3001
Description: IV administration of AAV and CRISPR/Cas9 gene editing system
Study NCT06179953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAO intervention
Description: The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts.
Study NCT06179953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional intervention
Description: The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts.
Study NCT06696794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (mitomycin) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
Study NCT06696794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (Normal Saline) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
Study NCT06697990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iruplinalib
Description: 60 mg of Iruplinalib, once daily for 7 days, followed by 180 mg of Iruplinalib, once daily in a 28-days cycle.
Study NCT06478615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coring out Fistulectomy with Closure of Internal Sphincter Opening
Description: The patient was laid in the lithotomy position. Skin preparation and draping were done. Normal saline irrigation was performed. The anal canal was sufficiently dilated to permit the introduction of a self-retaining retractor. With H2O2 injection into the fistula tract, the internal opening and tract of the fistula will be identified. The incision was made around the external opening, and the tract was all cored out along the tract from the external opening to the internal sphincter. Meticulous hemostasis will be performed, stay suture by PDS 4/0 around fistiolous opening at the internal sphincter, excision of fistulous tract above stay suture, then closure of internal sphincter defect by PDS 3/0. Anal packing with 4 × 4 epinephrine gauze and sterile protective dressing was performed. After the operation, a stool softener and pain controller were prescribed, and patients were discharged.
Study NCT06478615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lay Open Fistulotomy and Primary Sphincter Repair
Description: Patients were put in a lithotomy position and the skin was then draped. After identification of the external fistula orifice probing of the fistula tract with identification of the fistulous tract and internal orifice with H2O2 injection into the fistula tract. The fistula was laid open and fistulectomy was then conducted and dissected with diathermy cautery help. Then Primary repair of the sphincter with PDS 3/0 with proper hemostasis using coagulation diathermy.
Study NCT04635644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.
Study NCT04635644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
Study NCT05282693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ReMag
Description: 300 mg of ReMag dissolved in lemon flavor liquid
Study NCT05282693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lemon flavored liquid
Study NCT05090358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
Study NCT05090358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet
Description: Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
Study NCT05090358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
Study NCT06393530 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9%sodium chloride
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
Study NCT05090358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter.
Study NCT06393530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% ropivacaine
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
Study NCT05090358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
Study NCT06269601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upper Limb Rotation Test
Description: The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated.